ClinicalTrials.gov
Our mission is to improve cancer patients’ outcomes by ensuring each patient receives the right treatment, the first time.
Why does cell stiffness matter in cancer?
Cell stiffness plays a critical role in cancer progression and influences how cancer cells spread, interact, and respond to therapies. For example, a cancer cell needs to be able to physically squish and squeeze through the tissue in order to be able to successfully migrate and metastasize.
How can cell stiffness be measured?
Cell stiffness can be measured by applying a tiny force to the cell and observing how much it bends or resists, revealing its physical properties. We sometime refer to this as “nanopalpation”.
Where is ARTIDIS technology available?
Currently, ARTIDIS is being used in clinical studies at MD Anderson Cancer Center and Baylor College of Medicine in Houston, Texas. In 2025, we have plans to expand to more cities across the US and we will continue to update this list.
How is this technology different than liquid biopsies?
ARTIDIS measures tumor stiffness and other mechanical properties that are directly responsible for resistance or immediate metastasis formation, while liquid biopsies analyze circulating cancer markers in blood or other bodily fluids.
Ongoing Clinical Studies in Breast Cancer: incorporating ARTIDIS Platform into the standard of care clinical workflow
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
(ANGEL)
Currently Recruiting at Baylor College of Medicine, Houston TX
ClinicalTrials.gov
Trial of PreoperAtive Radiation (TOPAz):
a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
Currently Recruiting at MDA Cancer Center, Houston, Tx
ClinicalTrials.gov
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks
(EMPOWER)
Currently Recruiting at MDA Cancer Center, Houston, Tx
NCT05406232
ClinicalTrials.gov
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Currently Recruiting at MDA Cancer Center, Houston, Tx
Resources
click to download
ARTIDIS Technology Platform
The ARTIDIS device measures the physical properties of tissues, like cancer and it’s microenvironment, it is developed as an aid to diagnosis and treatment optimization tool for solid tumors.
Would you like to stay up to date with our upcoming events, recent publications, and clinical trials?
Sign up for our Newsletter to stay in touch:
